— Emilie Dubernay & Adam Hutchings
Despite the tremendous therapeutic advances delivered in rare diseases since the adoption of the Orphan Regulation in 2000, the European Commission has proposed a set of legislative revisions aimed at bolstering innovation whilst enhancing access and affordability. This study, based on a risk-adjusted Net Present Value framework, evaluates the expected impact on innovation in Europe of revisions within the next 15 years.
